Signant Health is simplifying the experience for patients, sites, and study teams to help you bring life-changing therapies to our families and communities around the world.

Testing new drugs is a slow, expensive, and manual process. Artificial intelligence has the potential to disrupt every stage of the clinical trials process — from matching eligible patients to studies to monitoring adherence and data collection. It’s not hard to guess why. For terminal illnesses like cancer, patients may only enroll in a drug trial when existing forms of treatments have already failed. On top of that, not all patients diagnosed with untreatable cancer are eligible to participate — even finding out if they are eligible is a herculean task for many. At Signant Health, their goal is to improve the lives of patients, sites, and study teams worldwide by providing simple, intuitive technology that simplifies clinical trials for everyone. Founded in 2018 from the merger of CRF Health and Bracket, Signant Health has emerged as a new leader in clinical trials, one that understands the patient journey, and uses their 20+ years’ experience to create technology by clinicians for clinicians.

These days, patients may not need to come to a clinic, site, or hospital in order to participate in clinical trials. Instead, trials have evolved alongside key advancements in technology, enabling patients to complete the entire trial, or a part of it, from the comfort of their own home. At Signant, they offer a broad set of remote trial components that enables you to choose which portions of the trial to conduct remotely. You can count on us for experience, technology, and the knowledge to help you administer aspects of your trial remotely, in a way that’s best for your patients, sites, and study teams.

Video Meetings and Patient Engagement

Now featuring video calls for complex remote clinician assessments, Signant’s Patient Engagement application TrialGuide is designed to simplify the lives of patients and sites worldwide, guiding them towards your trial’s key milestones. With TrialGuide, you receive:

• Video visits for patient and site interactions, ensuring that the same rapport and relationships established in office, continue remotely.
• Patient reminder notifications such as SMS, email, and in-app notifications
• Patient engagement features such as resource libraries, visits-by-visit guide, visit schedule and reminders, caregiver support, integration with third-party patient reimbursement solutions, gamification, patient surveys, and more.

With TrialConsent, your patients can access the entirety of the consent process from home, moving through the process at their own pace. Patients start by accessing credentials issued automatically to their verified email. From here, they can access your study’s consent documents ahead of visits or continue with the full consent consenting process without attending site. TrialConsent ensures that your patients understand what’s being asked of them by requiring that they flag sections as “understood”, or “have questions for the investigator” as they move through the consent process. With remote consenting, the review of these sections and questions can be performed by phone or video meeting with the site staff or via healthcare professionals at a delegated call centre.  TrialConsent can enhance and result in more focused direct-to-patient interaction by the sites, and allows this interaction to be maintained as a core component of the remote consent process. Patients and sites have full access to view and download signed consent forms.

Meet the leader behind the success of Signant Health

Roger Smith joined Signant Health as CEO to guide the company during an exciting time of evolution and growth. Roger is focused on realizing the company’s immense unlocked value by leading customers to aggressive adoption of eCOA, IRT, and Endpoint Solutions individually, as a platform to future direct-to-patient trial conduct. His vision is for Signant to lead the industry through product roadmap priorities, customer service excellence, commercial expansion, and most importantly, coming together as one culture around these principles. Roger joins Signant from PPD, where he was Senior Vice President and General Manager of Accelerated Enrollment Solutions (AES), which offers biopharmaceutical sponsors and contract research organizations best-in-class clinical trial site conduct and patient access solutions. In his role, he was responsible for AES’s strategic direction and financial growth as its chief executive, and played a pivotal role working closely with research sites and pharmaceutical organizations to solve patient recruitment challenges by utilizing digital technology and data science.  Prior to joining PPD in 2013 through its acquisition of Acurian, Mr. Smith held a number of senior management positions for Acurian, Kozmo.com and Sony Corporation. Roger brings decades of experience to the company and has a proven record of taking customer-centric technology and solutions companies like Signant Health to the next level by expanding the market for their services.

“We stand behind our dynamic solutions, serving as an extension of your study team while offering therapeutic area expertise and operational support you can trust”